August 14, 2026Stocks·Bullish·biotech
Rigel Pharmaceuticals launches VEPPANU commercially in the US
Rigel Pharmaceuticals announced VEPPANU is now commercially available in the US, launching the first approved therapy in a new treatment class following the FDA's May approval of vepdegestrant. The rollout marks a key commercial milestone for the company.
Detected & updated continuously · Source: Nebula
Story subjects
Sources
@TU_Crypto_News
Rigel Pharmaceuticals said VEPPANU is now commercially available in the U.S., launching the first approved therapy in a new treatment class. The rollout follows the FDA’s May approval of vepdegestrant and marks a key commercial milestone.
@SlartibartfastMcGee
It’s been all over the biotech sub and ST. It’s up for FDA approval tomorrow and that will be a bigger factor than a squeeze setup.